Prevalence, Risk Factors, Prognosis, and Management of Pericardial Effusion in COVID-19
<b>Background:</b> There is limited data in the literature about the clinical importance and prognosis of pericardial effusion (PE) in patients discharged after recovering from COVID-19, but large-scale studies have yet to be available. This study investigated the prevalence, risk factor...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-08-01
|
| Series: | Journal of Cardiovascular Development and Disease |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2308-3425/10/9/368 |
| _version_ | 1797579517324165120 |
|---|---|
| author | İbrahim Saraç Sidar Şiyar Aydın Murat Özmen Halil İbrahim Doru Gökhan Tonkaz Melike Nur Çırçır Furkan Akpınar Onur Zengin Orhan Delice Faruk Aydınyılmaz |
| author_facet | İbrahim Saraç Sidar Şiyar Aydın Murat Özmen Halil İbrahim Doru Gökhan Tonkaz Melike Nur Çırçır Furkan Akpınar Onur Zengin Orhan Delice Faruk Aydınyılmaz |
| author_sort | İbrahim Saraç |
| collection | DOAJ |
| description | <b>Background:</b> There is limited data in the literature about the clinical importance and prognosis of pericardial effusion (PE) in patients discharged after recovering from COVID-19, but large-scale studies have yet to be available. This study investigated the prevalence, risk factors, prognosis, late clinical outcomes, and management of PE in COVID-19. <b>Materials and Methods:</b> Between August 2020 and March 2021, 15,689 patients were followed up in our pandemic hospital due to COVID-19. Patients with positive polymerase chain reaction (PCR) test results and PE associated with COVID-19 in computed tomography (CT) were included in the study. The patients were divided into three groups according to PE size (mild, moderate, and large). Transthoracic echocardiography (TTE) records, laboratory data, clinical outcomes, and medical treatments of patients discharged from the hospital were retrospectively reviewed. <b>Results:</b> According to the PE size (mild, moderate, large) of 256 patients with PE at admission or discharge, the mean age was 62.17 ± 16.34, 69.12 ± 12.52, and 72.44 ± 15.26, respectively. The mean follow-up period of the patients was 25.2 ± 5.12 months. Of the patients in the study population, 53.5% were in the mild group, 30.4% in the moderate group, and 16.1% in the large group. PE became chronic in a total of 178 (69.6%) patients at the end of the mean three months, and chronicity increased as PE size increased. Despite the different anti-inflammatory treatments for PE in the acute phase, similar chronicity was observed. In addition, as the PE size increased, the patients’ frequency of hospitalization, complications, and mortality rates showed statistical significance between the groups. <b>Conclusions:</b> The clinical prognosis of patients presenting with PE was quite poor; as PE in size increased, cardiac and noncardiac events and mortality rates were significantly higher. Patients with large PE associated with COVID-19 at discharge should be monitored at close intervals due to the chronicity of PE and the increased risk of tamponade. |
| first_indexed | 2024-03-10T22:38:12Z |
| format | Article |
| id | doaj.art-6da631c8a41e4696a48c1be3d81b14f5 |
| institution | Directory Open Access Journal |
| issn | 2308-3425 |
| language | English |
| last_indexed | 2024-03-10T22:38:12Z |
| publishDate | 2023-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Cardiovascular Development and Disease |
| spelling | doaj.art-6da631c8a41e4696a48c1be3d81b14f52023-11-19T11:16:27ZengMDPI AGJournal of Cardiovascular Development and Disease2308-34252023-08-0110936810.3390/jcdd10090368Prevalence, Risk Factors, Prognosis, and Management of Pericardial Effusion in COVID-19İbrahim Saraç0Sidar Şiyar Aydın1Murat Özmen2Halil İbrahim Doru3Gökhan Tonkaz4Melike Nur Çırçır5Furkan Akpınar6Onur Zengin7Orhan Delice8Faruk Aydınyılmaz9Department of Cardiology, Erzurum City Hospital, Erzurum 25010, TurkeyDepartment of Cardiology, Erzurum City Hospital, Erzurum 25010, TurkeyDepartment of Cardiology, Erzurum City Hospital, Erzurum 25010, TurkeyDepartment of Emergency Medicine, Erzurum City Hospital, Erzurum 25010, TurkeyDepartment of Radiology, Giresun University Research Hospital, Giresun 28200, TurkeyDepartment of Emergency Medicine, Erzurum City Hospital, Erzurum 25010, TurkeyDepartment of Emergency Medicine, Erzurum City Hospital, Erzurum 25010, TurkeyDepartment of Emergency Medicine, Erzurum City Hospital, Erzurum 25010, TurkeyDepartment of Emergency Medicine, Erzurum City Hospital, Erzurum 25010, TurkeyDepartment of Cardiology, Erzurum City Hospital, Erzurum 25010, Turkey<b>Background:</b> There is limited data in the literature about the clinical importance and prognosis of pericardial effusion (PE) in patients discharged after recovering from COVID-19, but large-scale studies have yet to be available. This study investigated the prevalence, risk factors, prognosis, late clinical outcomes, and management of PE in COVID-19. <b>Materials and Methods:</b> Between August 2020 and March 2021, 15,689 patients were followed up in our pandemic hospital due to COVID-19. Patients with positive polymerase chain reaction (PCR) test results and PE associated with COVID-19 in computed tomography (CT) were included in the study. The patients were divided into three groups according to PE size (mild, moderate, and large). Transthoracic echocardiography (TTE) records, laboratory data, clinical outcomes, and medical treatments of patients discharged from the hospital were retrospectively reviewed. <b>Results:</b> According to the PE size (mild, moderate, large) of 256 patients with PE at admission or discharge, the mean age was 62.17 ± 16.34, 69.12 ± 12.52, and 72.44 ± 15.26, respectively. The mean follow-up period of the patients was 25.2 ± 5.12 months. Of the patients in the study population, 53.5% were in the mild group, 30.4% in the moderate group, and 16.1% in the large group. PE became chronic in a total of 178 (69.6%) patients at the end of the mean three months, and chronicity increased as PE size increased. Despite the different anti-inflammatory treatments for PE in the acute phase, similar chronicity was observed. In addition, as the PE size increased, the patients’ frequency of hospitalization, complications, and mortality rates showed statistical significance between the groups. <b>Conclusions:</b> The clinical prognosis of patients presenting with PE was quite poor; as PE in size increased, cardiac and noncardiac events and mortality rates were significantly higher. Patients with large PE associated with COVID-19 at discharge should be monitored at close intervals due to the chronicity of PE and the increased risk of tamponade.https://www.mdpi.com/2308-3425/10/9/368pericardial effusionprevalenceprognosismanagementCOVID-19 |
| spellingShingle | İbrahim Saraç Sidar Şiyar Aydın Murat Özmen Halil İbrahim Doru Gökhan Tonkaz Melike Nur Çırçır Furkan Akpınar Onur Zengin Orhan Delice Faruk Aydınyılmaz Prevalence, Risk Factors, Prognosis, and Management of Pericardial Effusion in COVID-19 Journal of Cardiovascular Development and Disease pericardial effusion prevalence prognosis management COVID-19 |
| title | Prevalence, Risk Factors, Prognosis, and Management of Pericardial Effusion in COVID-19 |
| title_full | Prevalence, Risk Factors, Prognosis, and Management of Pericardial Effusion in COVID-19 |
| title_fullStr | Prevalence, Risk Factors, Prognosis, and Management of Pericardial Effusion in COVID-19 |
| title_full_unstemmed | Prevalence, Risk Factors, Prognosis, and Management of Pericardial Effusion in COVID-19 |
| title_short | Prevalence, Risk Factors, Prognosis, and Management of Pericardial Effusion in COVID-19 |
| title_sort | prevalence risk factors prognosis and management of pericardial effusion in covid 19 |
| topic | pericardial effusion prevalence prognosis management COVID-19 |
| url | https://www.mdpi.com/2308-3425/10/9/368 |
| work_keys_str_mv | AT ibrahimsarac prevalenceriskfactorsprognosisandmanagementofpericardialeffusionincovid19 AT sidarsiyaraydın prevalenceriskfactorsprognosisandmanagementofpericardialeffusionincovid19 AT muratozmen prevalenceriskfactorsprognosisandmanagementofpericardialeffusionincovid19 AT halilibrahimdoru prevalenceriskfactorsprognosisandmanagementofpericardialeffusionincovid19 AT gokhantonkaz prevalenceriskfactorsprognosisandmanagementofpericardialeffusionincovid19 AT melikenurcırcır prevalenceriskfactorsprognosisandmanagementofpericardialeffusionincovid19 AT furkanakpınar prevalenceriskfactorsprognosisandmanagementofpericardialeffusionincovid19 AT onurzengin prevalenceriskfactorsprognosisandmanagementofpericardialeffusionincovid19 AT orhandelice prevalenceriskfactorsprognosisandmanagementofpericardialeffusionincovid19 AT farukaydınyılmaz prevalenceriskfactorsprognosisandmanagementofpericardialeffusionincovid19 |